US: 800.298.5699
Int'l: +1.240.747.3093
Latest Research by Email
Receive email alerts of new market research reports in your industry.
Sign Up Today >
|
Home > List All Publishers > Decision Resources
Decision Resources
For almost three decades, Decision Resources has provided in-depth research on the trends, emerging developments, and market potential of the drug industry. Large pharmaceutical companies as well as startup biotechs turn to Decision Resources for the information they need to license, market, and compete. The privately owned company offers research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Using both primary and secondary resources, their highly credentialed in-house staff studies surveys and data, and conduct interviews with physicians to determine the status of a variety of diseases and drugs. By more...
|

|
|
Title
|
Published
|
Price
|
|
Drug Price/Cost Debate: Coping with Escalating Pricing Pressures
By: Decision Resources
Introduction
Insinuations of profi teering were made against an H1N1 swine flu vaccine manufacturer in the summer of 2009.
As the swine flu epidemic began to take on serious proportions, public scrutiny in the United
|
more...
|
11/9/2009
|
$2,250.00
|
|
Dealmaking and Industry Outlook: Neurological Disease
By: Decision Resources
The plethora of recent reports of new genes and pathways linked to neurological diseases shows that the underlying
causes of these diseases are far from certain; as a result, therapeutic strategies in effect today may
|
more...
|
11/2/2009
|
$2,250.00
|
|
H4-13, Market Access, Pricing, and Reimbursement News in the Third Quarter of 2009
By: Decision Resources
Introduction:
The third quarter of 2009 saw a heated debate in the United States over healthcare reform, the publication of a
report on a European investigation of the pharmaceutical industry, the election of new governments
|
more...
|
10/28/2009
|
$2,250.00
|
|
Biomarker and Diagnostic Opportunities in Clinical Research for Neurological Diseases
By: Decision Resources
Introduction
Biomarkers and imaging tools are enabling technologies in today’s clinical research efforts for neurological
diseases. Whether to improve upon existing methods for monitoring disease progression or to discover validated
measures to detect diseases earlier
|
more...
|
10/13/2009
|
$2,250.00
|
|
Special Report: The Pandemic Paradigm: Balancing Commercial Opportunities with Public Health Concerns in the Face of A/H1N1 2009
By: Decision Resources
Introduction
WHO and the European Centre for Disease Prevention and Control (ECDC) are advising countries to prepare
for a more severe second wave of A/H1N1 2009 in the winter of 2009-2010. This advisement could be
|
more...
|
10/13/2009
|
$4,500.00
|
|
Innovation, Health Technology Assessment, and Comparative Effectiveness Research: The Obstacle Course to Market Access
By: Decision Resources
Introduction:
The use of health technology assessment (HTA) is growing steadily in Europe, and the U.S. government
has recently announced $1.1 billion in funding for comparative effectiveness research (CER)
as part of its planned overhaul
|
more...
|
9/25/2009
|
$2,250.00
|
|
Pharmaceutical Pricing and Reimbursement in India
By: Decision Resources
Introduction
Faced with a dramatic slowdown in sales in mature pharmaceutical markets, multinational pharmaceutical companies
are looking to substantially increase their sales in India and other emerging markets. The Indian market
is growing by more
|
more...
|
9/25/2009
|
$2,250.00
|
|
SPECIAL REPORT: Can Innovation Supplant Convention in Sarcoidosis Treatment?
By: Decision Resources
Introduction
“I’d love there to be a better agent,” says a thought leader on the current state of sarcoidosis treatment. Many
sarcoidosis patients require little or no treatment, but patients with chronic disease need a
|
more...
|
9/23/2009
|
$4,500.00
|
|
Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?
By: Decision Resources
Introduction
Can radical changes to the structures and strategies of pharmaceutical R&D operations—such as
creating more entrepreneurial environments modeled upon biotech companies—increase their productivity?
Many major companies are reorganizing the research branches of their businesses
|
more...
|
9/18/2009
|
$2,250.00
|
|
Disruption or Advantage? Update on Companion Diagnostics
By: Decision Resources
Introduction
Some naysayers disagree, but we regard companion diagnostics as a win-win scenario for all stakeholders.
Companion diagnostics combines drug and diagnostic test development. The potential for effi cient drug development
is huge because companion
|
more...
|
9/15/2009
|
$2,250.00
|
|
A Global Recession Drives New Business Strategies and Evolving Business Models in the Biopharma Industry
By: Decision Resources
The biotechnology and pharmaceutical sectors as we know them will soon cease to exist. Companies in these
sectors have come face-to-face with the harrowing ordeals of a global recession. Four stresses on the industry
are
|
more...
|
9/15/2009
|
$2,250.00
|
|
The 111th U.S. Congress Tackles Healthcare Reform and the Pharmaceutical Industry
By: Decision Resources
In this report
we feature a commentary by Alex M. Brill, CEO of Matrix Global Advisors and
a research fellow at the American Enterprise Institute, who testifi ed before the U.S.
House Judiciary Committee’s
|
more...
|
9/10/2009
|
$2,250.00
|
|
Biopharma Quarter: Key Trends and Events of the Second Quarter of 2009
By: Decision Resources
The first Phase 0 trial results, thefirst fruits of Japan’s biosimilar pathway, the first straightforward use of the social
marketing tool Twitter to advance a drug franchise, thefirst moves of the EU to regulate third-party
|
more...
|
9/10/2009
|
$2,250.00
|
|
The Pricing and Reimbursement Environment for Neurology Drugs
By: Decision Resources
Introduction:
Neurological disorders will impose a growing social and financial burden on the major pharmaceutical markets
as the elderly population in these countries increases steadily. Governments and other payers recognize the
pressing need to tackle
|
more...
|
8/31/2009
|
$2,250.00
|
|
Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec
By: Decision Resources
Introduction
Chronic myelogenous leukemia (CML) is a rare blood cancer; nonetheless, CML treatments garner substantial
revenues. Despite recent advances in the treatment of this disease (most notably, targeted therapeutics such as
Novartis’s Gleevec/Glivec [imatinib]), significant
|
more...
|
8/27/2009
|
$2,250.00
|
|
Uncovering Biomarker and Diagnostic Opportunities in Immune and Inflammatory Diseases
By: Decision Resources
Introduction
Despite the robust drug market for immune and infl ammatory diseases and their high prevalence, diagnostics associated
with these diseases do not constitute a large marketplace. Although researchers are working to discover
biomarkers, associate
|
more...
|
8/21/2009
|
$2,250.00
|
|
Neurological Disease: Early-Stage R&D and Dealmaking
By: Decision Resources
Introduction
How can early-stage R&D efforts be positioned to tap the remaining opportunity in the neurology
drug market? Although brimming with potential, neurology drug development is also rife with unique
challenges that many companies and
|
more...
|
8/20/2009
|
$2,250.00
|
|
Monitoring Health Through Novel Technologies: Where Are We with Point-of-Care Diagnostics?
By: Decision Resources
Introduction
The point-of-care (POC) diagnostics segment of the in vitro diagnostics fi eld once largely consisted of glucosemonitoring
devices. With billions of dollars generated in revenue in the United States alone, POC testing has
blossomed
|
more...
|
8/20/2009
|
$2,250.00
|
|
Special Report - The Autism Spectrum Disorders Market: Substantial Opportunity and Unique Challenges
By: Decision Resources
Introduction
An increase in public funding for research and a heightened interest among drug developers suggest that a
breakthrough in autism spectrum disorder (ASD) treatment may be imminent. However, drug development has
been slow, plagued
|
more...
|
8/18/2009
|
$4,500.00
|
|
Market Access, Pricing, and Reimbursement News in the Second Quarter of 2009
By: Decision Resources
Introduction
The second quarter of 2009 saw steady progress toward healthcare reform in the United States and action in
several of the world’s other major pharmaceutical markets to curb pharmaceutical expenditures. Cost-containment
strategies vary considerably
|
more...
|
8/6/2009
|
$2,250.00
|
|
The Neurology Pipeline: A Strategic Review
By: Decision Resources
Mega-blockbuster status would be quick and sure for any safe, effective agent that prevents the death and
damage of neurons associated with neurodegenerative diseases. The potential of such a neuroprotectant is one
of the motivations
|
more...
|
8/3/2009
|
$2,250.00
|
|
Strategies for Building Early-Stage Pipelines Through External Sources
By: Decision Resources
Introduction
Under tremendous pressure to refuel dwindling development pipelines and improve R&D productivity,
pharmaceutical companies are seeking external sources of products and innovation. Biotech companies
offer valuable technologies, targets, and compounds. Pharma companies best able
|
more...
|
7/30/2009
|
$2,250.00
|
|
Dealmaking and Industry Outlook: Autoimmune and Inflammatory Diseases
By: Decision Resources
Introduction
Better diagnostics, the means to treat earlier stage-disease, disease-modifying therapies, and disease prevention
are the holy grails of autoimmune and infl ammatory disease drug development. However, basic science and
redundant biological pathways are holding
|
more...
|
7/27/2009
|
$2,250.00
|
|
The Psychiatric Disease Pipeline: A Strategic Review
By: Decision Resources
Numbers tell the story in psychiatric disease drug development: almost 300 recognized indications,
28% 12-month prevalence that yields large patient populations, strong 7.5% annual sales growth in
recent years, sustained franchise sales, tolerance for use
|
more...
|
7/22/2009
|
$2,250.00
|
|
Pharmaceutial Pricing and Reimbursement in China
By: Decision Resources
Introduction
With a growth rate of more than 20% per year, the Chinese pharmaceutical market is set to become the third
largest in the world in 2011. A radical healthcare reform package recently unveiled by
|
more...
|
6/29/2009
|
$2,250.00
|
|
Title
|
Published
|
Price
|
|
|